Latest fiscal year 2022 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2022, Elicio Therapeutics, Inc. reported revenue of $2M, down 91.9% year over year. Operating margin was -1031.4% and net margin -1225.9%, on a free-cash-flow margin of -992.3% with capital expenditure at 28.4% of revenue. Every figure is computed directly from ELTX's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2022 | $2M | -1031.4% | -1225.9% |
| FY2021 | $28M | -138.8% | -192.8% |
| FY2020 | $3M | -1919.2% | -2781.5% |
How does ELTX compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.